Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey

Hong Zhao; Aiping Zhou; Jianguo Zhou; Xinyu Bi; Shida Yan; Jing Jin; Wenqiang Wei; Muxing Li; Caifeng Gong; Qichen Chen; Zhiwen Luo; Ning Li; Rui Mao; Xiao Chen; Bo Chen; Rongshou Zheng; Jianjun Zhao; Yue Han; Zhiyu Li; Xu Che; Yuan Tang; Yongkun Sun; Zhen Huang; Yefan Zhang; Xiaoying Wang; Yubao Zhang; Zhenhui Lu; Xiaowei Dang; Tianqiang Song; Chang Liu; Ping Yue; Dong Yan; Aimin Yue; Rui Zhang; Suxia Luo; Jing Tan; Xuewen Zhang; Xueli Bai; Xuejun Zhang; Mingyan He; Yujun Xie; Wenling Wang; Po Yang; Yijun Yang; Yamin Zhang; Qingdong Li; Tao Peng; Zusen Wang; Yajin Chen; Changzhen Shang; Yingjian Liang; Bixiang Zhang; Feng Zhang; Liming Wang; Duo Li; Bin Liu; Xiaofeng Zhu; Qinggang Hu; Minshan Chen; Dianrong Xiu; Feng Xia; Yanqiao Zhang; Yong Zeng; Yilei Mao; Xun Li; Yi Ba; Tingbo Liang; Feng Shen; Lianxin Liu; Xiujun Cai; Jian Zhou; Jianqiang Cai

doi:10.1016/j.hpb.2021.07.002

Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey

Hong Zhao
, Aiping Zhou
, Jianguo Zhou
, Xinyu Bi
, Shida Yan
, Jing Jin
, Wenqiang Wei
, Muxing Li
, Caifeng Gong
, Qichen Chen
, Zhiwen Luo
, Ning Li
, Rui Mao
, Xiao Chen
, Bo Chen
, Rongshou Zheng
, Jianjun Zhao
, Yue Han
, Zhiyu Li
, Xu Che

Yuan Tang, Yongkun Sun, Zhen Huang, Yefan Zhang, Xiaoying Wang, Yubao Zhang, Zhenhui Lu, Xiaowei Dang, Tianqiang Song, Chang Liu, Ping Yue, Dong Yan, Aimin Yue, Rui Zhang, Suxia Luo, Jing Tan, Xuewen Zhang, Xueli Bai, Xuejun Zhang, Mingyan He, Yujun Xie, Wenling Wang, Po Yang, Yijun Yang, Yamin Zhang, Qingdong Li, Tao Peng, Zusen Wang, Yajin Chen, Changzhen Shang, Yingjian Liang, Bixiang Zhang, Feng Zhang, Liming Wang, Duo Li, Bin Liu, Xiaofeng Zhu, Qinggang Hu, Minshan Chen, Dianrong Xiu, Feng Xia, Yanqiao Zhang, Yong Zeng, Yilei Mao, Xun Li, Yi Ba, Tingbo Liang, Feng Shen, Lianxin Liu, Xiujun Cai, Jian Zhou, Jianqiang Cai

Chinese Academy of Medical Sciences
Peking University
Fudan University
Harbin Medical University
Ningxia Medical University
First Affiliated Hospital of Zhengzhou University
Tianjin Medical University
The First Affiliated Hospital of Xi’an Jiaotong University
Lanzhou University
Xinjiang Medical University
Xinxiang Central Hospital
China Medical University
Henan Cancer Hospital
Kunming Medical College
Jilin University
Zhejiang University School of Medicine
Inner Mongolia People's Hospital
Gansu Provincial Cancer Hospital
Ningxia People's Hospital
Guizhou Medical University
Central South University
Tianjin First Central Hospital
Chongqing University Cancer Hospital
The First Affiliated Hospital of Guangxi Medical University
Qingdao University
Sun Yat-sen Memorial Hospital of Sun Yat sen University
The First Affiliated Hospital of Harbin Medical University
Huazhong University of Science and Technology
Hubei Cancer Hospital
Dalian Medical University
Hainan Cancer Hospital
Sun Yat-Sen University
Sun Yat-Sen University Cancer Center
Chongqing Medical University
Sichuan University
Naval Medical University
The First Affiliated Hospital of University of Science and Technology of China
Sir Run Run Shaw Hospital

科研成果: 期刊稿件 › 文章 › 同行评审

6 引用（Scopus）

摘要

Background: This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic. Methods: A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic. Results: 716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the “face-to-face” visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC. Discussion: During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.

源语言	英语
页（从-至）	342-352
页数	11
期刊	HPB
卷	24
期	3
DOI	https://doi.org/10.1016/j.hpb.2021.07.002
出版状态	已出版 - 3月 2022
已对外发布	是

访问文件

10.1016/j.hpb.2021.07.002

其它文件与链接

链接到 Scopus 的出版物

引用此

Zhao, H., Zhou, A., Zhou, J., Bi, X., Yan, S., Jin, J., Wei, W., Li, M., Gong, C., Chen, Q., Luo, Z., Li, N., Mao, R., Chen, X., Chen, B., Zheng, R., Zhao, J., Han, Y., Li, Z., ... Cai, J. (2022). Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey. HPB, 24(3), 342-352. https://doi.org/10.1016/j.hpb.2021.07.002

@article{23df160d3a5d40ec927fc5a60dd16a79,

title = "Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey",

abstract = "Background: This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic. Methods: A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic. Results: 716 doctors responded effectively with a response rate of 60.1\%, and 664 were included in the final analysis. Overall, 51.4\% (341/664) of clinicians reported more than a 60\% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5\% (614/664) of the respondents have been using online medical consultation to substitute for the {\textquotedblleft}face-to-face{\textquotedblright} visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC. Discussion: During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.",

author = "Hong Zhao and Aiping Zhou and Jianguo Zhou and Xinyu Bi and Shida Yan and Jing Jin and Wenqiang Wei and Muxing Li and Caifeng Gong and Qichen Chen and Zhiwen Luo and Ning Li and Rui Mao and Xiao Chen and Bo Chen and Rongshou Zheng and Jianjun Zhao and Yue Han and Zhiyu Li and Xu Che and Yuan Tang and Yongkun Sun and Zhen Huang and Yefan Zhang and Xiaoying Wang and Yubao Zhang and Zhenhui Lu and Xiaowei Dang and Tianqiang Song and Chang Liu and Ping Yue and Dong Yan and Aimin Yue and Rui Zhang and Suxia Luo and Jing Tan and Xuewen Zhang and Xueli Bai and Xuejun Zhang and Mingyan He and Yujun Xie and Wenling Wang and Po Yang and Yijun Yang and Yamin Zhang and Qingdong Li and Tao Peng and Zusen Wang and Yajin Chen and Changzhen Shang and Yingjian Liang and Bixiang Zhang and Feng Zhang and Liming Wang and Duo Li and Bin Liu and Xiaofeng Zhu and Qinggang Hu and Minshan Chen and Dianrong Xiu and Feng Xia and Yanqiao Zhang and Yong Zeng and Yilei Mao and Xun Li and Yi Ba and Tingbo Liang and Feng Shen and Lianxin Liu and Xiujun Cai and Jian Zhou and Jianqiang Cai",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = mar,

doi = "10.1016/j.hpb.2021.07.002",

language = "英语",

volume = "24",

pages = "342--352",

journal = "HPB",

issn = "1365-182X",

publisher = "Elsevier B.V.",

number = "3",

}

Zhao, H, Zhou, A, Zhou, J, Bi, X, Yan, S, Jin, J, Wei, W, Li, M, Gong, C, Chen, Q, Luo, Z, Li, N, Mao, R, Chen, X, Chen, B, Zheng, R, Zhao, J, Han, Y, Li, Z, Che, X, Tang, Y, Sun, Y, Huang, Z, Zhang, Y, Wang, X, Zhang, Y, Lu, Z, Dang, X, Song, T, Liu, C, Yue, P, Yan, D, Yue, A, Zhang, R, Luo, S, Tan, J, Zhang, X, Bai, X, Zhang, X, He, M, Xie, Y, Wang, W, Yang, P, Yang, Y, Zhang, Y, Li, Q, Peng, T, Wang, Z, Chen, Y, Shang, C, Liang, Y, Zhang, B, Zhang, F, Wang, L, Li, D, Liu, B, Zhu, X, Hu, Q, Chen, M, Xiu, D, Xia, F, Zhang, Y, Zeng, Y, Mao, Y, Li, X, Ba, Y, Liang, T, Shen, F, Liu, L, Cai, X, Zhou, J & Cai, J 2022, 'Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey', HPB, 卷 24, 号码 3, 页码 342-352. https://doi.org/10.1016/j.hpb.2021.07.002

TY - JOUR

T1 - Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic

T2 - a nationwide multicenter survey

AU - Zhao, Hong

AU - Zhou, Aiping

AU - Zhou, Jianguo

AU - Bi, Xinyu

AU - Yan, Shida

AU - Jin, Jing

AU - Wei, Wenqiang

AU - Li, Muxing

AU - Gong, Caifeng

AU - Chen, Qichen

AU - Luo, Zhiwen

AU - Li, Ning

AU - Mao, Rui

AU - Chen, Xiao

AU - Chen, Bo

AU - Zheng, Rongshou

AU - Zhao, Jianjun

AU - Han, Yue

AU - Li, Zhiyu

AU - Che, Xu

AU - Tang, Yuan

AU - Sun, Yongkun

AU - Huang, Zhen

AU - Zhang, Yefan

AU - Wang, Xiaoying

AU - Zhang, Yubao

AU - Lu, Zhenhui

AU - Dang, Xiaowei

AU - Song, Tianqiang

AU - Liu, Chang

AU - Yue, Ping

AU - Yan, Dong

AU - Yue, Aimin

AU - Zhang, Rui

AU - Luo, Suxia

AU - Tan, Jing

AU - Zhang, Xuewen

AU - Bai, Xueli

AU - Zhang, Xuejun

AU - He, Mingyan

AU - Xie, Yujun

AU - Wang, Wenling

AU - Yang, Po

AU - Yang, Yijun

AU - Zhang, Yamin

AU - Li, Qingdong

AU - Peng, Tao

AU - Wang, Zusen

AU - Chen, Yajin

AU - Shang, Changzhen

AU - Liang, Yingjian

AU - Zhang, Bixiang

AU - Zhang, Feng

AU - Wang, Liming

AU - Li, Duo

AU - Liu, Bin

AU - Zhu, Xiaofeng

AU - Hu, Qinggang

AU - Chen, Minshan

AU - Xiu, Dianrong

AU - Xia, Feng

AU - Zhang, Yanqiao

AU - Zeng, Yong

AU - Mao, Yilei

AU - Li, Xun

AU - Ba, Yi

AU - Liang, Tingbo

AU - Shen, Feng

AU - Liu, Lianxin

AU - Cai, Xiujun

AU - Zhou, Jian

AU - Cai, Jianqiang

PY - 2022/3

Y1 - 2022/3

N2 - Background: This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic. Methods: A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic. Results: 716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the “face-to-face” visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC. Discussion: During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.

AB - Background: This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic. Methods: A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic. Results: 716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the “face-to-face” visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC. Discussion: During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.

UR - https://www.scopus.com/pages/publications/85112684535

U2 - 10.1016/j.hpb.2021.07.002

DO - 10.1016/j.hpb.2021.07.002

M3 - 文章

C2 - 34400051

AN - SCOPUS:85112684535

SN - 1365-182X

VL - 24

SP - 342

EP - 352

JO - HPB

JF - HPB

IS - 3

ER -

Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey

摘要

访问文件

其它文件与链接

学术指纹

引用此